| Features: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Linalool — Linalool is a naturally occurring acyclic monoterpene tertiary alcohol and volatile terpene found in many essential oils, including lavender, coriander, basil, rosewood, and citrus-associated oils. It is formally classified as a small-molecule phytochemical / monoterpenoid fragrance and flavor compound, commonly abbreviated as LIN or Lin. It exists as enantiomers with different odor profiles and biological handling. In oncology research, linalool is best treated as a preclinical bioactive terpene with in-vitro and limited animal-model anticancer signals, not as a clinically validated anticancer therapy. Primary mechanisms (ranked):
Bioavailability / PK relevance: Linalool is volatile and lipophilic, with systemic exposure possible after oral, inhaled, and transdermal routes, but therapeutic plasma levels for anticancer effects remain uncertain. Human oral PK methods have been developed, and inhalation/transdermal studies support absorption, but most anticancer experiments use concentrations that are difficult to map directly to achievable human exposure. In-vitro vs systemic exposure relevance: Many anticancer studies use high micromolar to millimolar linalool concentrations, especially in lung, liver, leukemia, prostate, and colon cancer cell models. These levels may exceed realistic systemic exposure from food, fragrance, aromatherapy, or ordinary essential-oil use. Direct anticancer interpretation should therefore be concentration-constrained. Clinical evidence status: Preclinical. Linalool itself has no established cancer-treatment indication. Human studies involving linalool-rich essential oils or aromatherapy are mainly supportive-care studies for anxiety, sleep, pain, or procedural distress, not tumor-response trials. Regulatory status is primarily as a flavor/fragrance substance, not as an approved oncology drug. Linalool Cancer Mechanism Table
TSF legend: P: 0–30 min R: 30 min–3 hr G: >3 hr |
| Source: |
| Type: |
| The selectivity of cancer products (such as chemotherapeutic agents, targeted therapies, immunotherapies, and novel cancer drugs) refers to their ability to affect cancer cells preferentially over normal, healthy cells. High selectivity is important because it can lead to better patient outcomes by reducing side effects and minimizing damage to normal tissues. Achieving high selectivity in cancer treatment is crucial for improving patient outcomes. It relies on pinpointing molecular differences between cancerous and normal cells, designing drugs or delivery systems that exploit these differences, and overcoming intrinsic challenges like tumor heterogeneity and resistance Factors that affect selectivity: 1. Ability of Cancer cells to preferentially absorb a product/drug -EPR-enhanced permeability and retention of cancer cells -nanoparticle formations/carriers may target cancer cells over normal cells -Liposomal formations. Also negatively/positively charged affects absorbtion 2. Product/drug effect may be different for normal vs cancer cells - hypoxia - transition metal content levels (iron/copper) change probability of fenton reaction. - pH levels - antiOxidant levels and defense levels 3. Bio-availability |
| 6464- | LIN, | 1,8-Cin, | Anti-cancer mechanisms of linalool and 1,8-cineole in non-small cell lung cancer A549 cells |
| - | in-vitro, | NSCLC, | A549 | - | in-vitro, | Nor, | WI38 |
| 6479- | LIN, | Anticancer effect of linalool via cancer-specific hydroxyl radical generation in human colon cancer |
| - | in-vivo, | Colon, | HCT116 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:410 Target#:1110 State#:% Dir#:2
wNotes=0 sortOrder:rid,rpid